BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31360119)

  • 1. Search for Novel Diagnostic Biomarkers of Prostate Inflammation-Related Disorders: Role of Transglutaminase Isoforms as Potential Candidates.
    Savoca MP; Inferrera A; Verderio EAM; Caccamo D
    Mediators Inflamm; 2019; 2019():7894017. PubMed ID: 31360119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer.
    Cho SY; Choi K; Jeon JH; Kim CW; Shin DM; Lee JB; Lee SE; Kim CS; Park JS; Jeong EM; Jang GY; Song KY; Kim IG
    Exp Mol Med; 2010 Apr; 42(4):310-8. PubMed ID: 20177144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
    Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
    Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
    Birckbichler PJ; Bonner RB; Hurst RE; Bane BL; Pitha JV; Hemstreet GP
    Cancer; 2000 Jul; 89(2):412-23. PubMed ID: 10918174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
    De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
    Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
    Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
    Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer.
    Lewis TE; Milam TD; Klingler DW; Rao PS; Jaggi M; Smith DJ; Hemstreet GP; Balaji KC
    Urol Oncol; 2005; 23(6):407-12. PubMed ID: 16301118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
    Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
    Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
    Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
    Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.
    Luna-Coronell JA; Vierlinger K; Gamperl M; Hofbauer J; Berger I; Weinhäusel A
    Proteomics; 2016 Apr; 16(8):1204-14. PubMed ID: 27089054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can expressed prostatic secretions effect prostate biopsy decision of urologist?
    Ergun O; Capar E; Goger YE; Ergun AG
    Int Braz J Urol; 2019; 45(2):246-252. PubMed ID: 30648827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary approach to prostatitis.
    Magri V; Boltri M; Cai T; Colombo R; Cuzzocrea S; De Visschere P; Giuberti R; Granatieri CM; Latino MA; Larganà G; Leli C; Maierna G; Marchese V; Massa E; Matteelli A; Montanari E; Morgia G; Naber KG; Papadouli V; Perletti G; Rekleiti N; Russo GI; Sensini A; Stamatiou K; Trinchieri A; Wagenlehner FME
    Arch Ital Urol Androl; 2019 Jan; 90(4):227-248. PubMed ID: 30655633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study.
    Kaya E; Ozgok Y; Zor M; Eken A; Bedir S; Erdem O; Ebiloglu T; Ergin G
    Adv Clin Exp Med; 2017 Oct; 26(7):1095-1099. PubMed ID: 29211357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.
    Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G
    Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.